Please use this identifier to cite or link to this item:
標題: Clinical outcome in dogs with cutaneous mast cell tumors treated with neoadjuvant prednisolone and surgical excision
作者: Hui-Ju Wang
關鍵字: 肥大細胞瘤;前導型藥物prednisolone;Mast cell tumor;neoadjuvant prednisolone
引用: Asboe-Hansen, G., 1952. Cortisone action. Proceedings of Society for Experimental Biology 80, 677-679. Al-Sarraf, R., Mauldin, G.N., Patnaik, A.K., Meleo, K.A., 1996. A prospective study of radiation therapy for the treatment of grade 2 mast cell tumors in 32 dogs. Journal of Veterinary Internal Medicine 10, 376-378. Abadie, J.J., Amardeilh, M.A., Delverdier, M.E., 1999. Immunohistochemical detection of proliferating cell nuclear antigen and Ki-67 in mast cell tumors from dogs. Journal of the American Veterinary Medical Association 215, 1629-1634. Abbas, A.K., Lichtman, A.H., Pober, J.S., 2000. Immediate hypersensitivity. In: Abbas, A.K., Lichtman, A.H., Pober, J.S., eds. Cellular and Molecular Immunology. Philadelphia, U.S.A.: WB Saunders Co, 424-438. Andrade, M.V., Hiragun, T., Beaven, M.A., 2004. Dexamethasone suppresses antigen-induced activation of phosphatidylinositol 3-kinase and downstream responses in mast cells. Journal of Immunology 172, 7254-7262. Bloom, F., 1952. Effects of cortisone on canine mast cell tumor. Proceeding of The Society for Experimental Biology and Medicine 80, 651-654. Brodey, R.S., McGrath, J.T., Martin, J.E., 1953. Preliminary observations on the use of cortisone in canine mast cell sarcoma. Journal of the American Veterinary Medical Association 123, 391-394. Brodey, R.S., 1970. Canine and feline neoplasia. In: Brandy, C.A., Cornelius, C.E., eds. Advances in Veterinary Science and Comparative Medine. New York, U.S.A.: Academic Press, 14, 309-354. Bostock, D.E., 1973. The prognosis following surgical removal of mastocytomas in dogs. The Journal of Small Animal Practice 14, 27-41. Byers, J.C., Fleischman, R.W., 1981. Peptic ulcers associated with a mast cell tumor in a dog. Canine Practice 8, 42-44. Bradbeer, J., 1985. Treatment of primary breast cancer in elderly with 'No-valdex' alone. Rev Endocrine-related cancer 16, 39-42. Barthez, P., 1993. Perforating ulcer in a canine patient with mastocytosis. Point Veterinaire 25, 79-81. Behrend, E.N., Kemppainen, R.J., 1997. Glucocorticoid therapy. Pharmacology, indications, and complications. Veterinary Clinics of North America: Small Animal Practice 27, 187-213. Brizzi, M.F., Zini, M.G., Aronica, M.G., Blechman, J.M., Yarden, Y., Pegoraro, L., 1997. Convergence of signaling by interleukin-3, granulocyte-macrophage colony stimulating factor and mast cell growth-factor on jak2 tyrosine kinase. The Journal of Biological Chemistry 272, 27450-27455. Buchdunger, E., O'Reilly, T., Wood, J., 2002. Pharmacology of imatinib (ST1571). European Journal of Cancer 38(Supplement 5), 28-36. Baker-Gabb, M., Hunt, G.B., France, M.P., 2003. Soft tissue sarcomas and mast cell tumors in dogs: Clinical behavior and response to surgery. Australian Veterinary Journal 81(12) 732-738. Barnes, P.J., Adcock, I.M., 2009. Glucocorticoid resistance in inflammatory disease. Lancet 373, 1905-1917. Blackwood, L., Murphy, S., Buracco, P., De Vos, J.P., De Fornel-Thibaud, P.,Hirschberger, J., et al., 2012. European consensus decument on mast cell tumours in dogs and cats. Veterinary and Comparative Oncology 10, e1-e29. Crowe, D.T.Jr., Goodwin, M.A., Greene, C.E., 1986. Total laryngectomy for laryngeal mast cell tumor in a dog. Journal of the American Animal Hospital Association 22, 809-816. Clark, D.M., Harvey, H.J., Roth, L., Callihan, D.R., 1986. Clostridial peritonitis associated with a mast cell tumor in a dog. Journal of the American Veterinary Medical Association 188, 188-190. Carberry, C.A., Flanders, J.A., Anderson, W.I., Harvey, H.J., 1987. Mast cell tumor in the mandibular salivary gland in a dog. Cornell Veterinarian 77, 362-366. Chun, R., Garrett, L., MacEwen, E.G., 2001. Mast cell tumors. In: Withrow, S.J., MacEwen, E.G., eds. Small Animal Clinical Oncology. Philadelphia, U.S.A.: WB Saunder, 92-118. Cheong, Y.C., Laird, S.M., Shelton, J.B., Ledger, W.L., Li, T.C., Cooke, I.D., 2002. The correlation of adhesions and peritoneal fluid cytokine concentrations: a pilot study. Human Reproduction 17, 1039-1045. Dean, P.W., 1988. Mast cell tumors in dogs: diagnosis, treatment, and prognosis. Veterinary Medicine 83, 185-188, 190-192. Druker, B.J., Talpaz, M., Resta, D.J., Prng, B., Buchdunger, E., Ford, J.M., et al., 2001. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. The New England Journal of the Medicine 344, 1031-1037. De Souza, M.L., Torres, L.F., Rocha, N.S., Takahira, R.K., Mamprim, M.J., Burini, C.H.P., et al., 2001. Peritoneal effusion in a dog secondary to visceral mast cell tumor. A case report. Acta Cytologica 45, 89-92. Demetri, G.D., von Mehren, M., Blanke, C.D., den Abbeele, A.D.V., Eisenberg, B., Roberts, P.J., et al., 2002. Efficacy and safety imatinib mesylate in advanced gastrointestinal stromal tumors. The New England Journal of the Medicine 347, 472-480. Dobson, J., Cohen, S., Gould, S., 2004. Treatment of canine mast cell tumors with prednisolone and radiotherapy. Veterinary and Comparative Oncology 2, 132-141. Eckersley, G.N., Bastianello, S., Van Heerden, J., Williams, J.H., 1989. An expansile secondary hypophyseal mastocytoma in a dog. Journal of the South African Veterinary Association 60, 113-116. Elmslie, R., 1997. Combination chemotherapy with and without surgery for dogs with high grade mast cell tumors with regional lymph node metastases. Veterinary Cancer Society Newsletter 20, 6-7. Finnie, J.W., Bostock, D.E., 1979. Skin neoplasia in dogs. Australian Veterinary Journal 55, 602-604. Frimberger, A.E., Moore, A.S., Larue, S.M., Gliatto, J.M., Bengtson, A.E., 1997. Radiotherapy of incompletely resected, moderately differentiated mast cell tumors in the dog – 37 cases (1989-1993). Journal of the American Animal Hospital Association 33(4), 320-324. Finotto, S., Mekori, Y.A., Metcalfe, D.D., 1997. Glucocorticoids decrease tissue mast cell number by reducing the production of the c-kit ligand, stem cell factor, by resident cells: in vitro and in vivo evidence in murine systems. Journal of Clinical Investigation 99, 1721-1728. Fan, T.M., Kitchell, B.E., 1999. Retrospective analysis of oral mast cell tumors in dogs. Proceeding 19th Annual Veterinary Cancer Society Conference 40. Fulcher,. RP., Ludwig, L.L., Bergman, P.J., Newman, S.J., Simpson, A.M., Pataik, A.K., 2006. Evaluation of a two-centimeter lateral surgical margin for excision of grade I and grade II cutaneous mast cell tumors in dogs. Journal of the American Veterinary Medical Association 228, 210-215. Goldschmidt, M.H., Shofer, F.S., 1992. Mast cell tumors. In: Edney, A.T.B., eds. Skin tumors of the dog and cat. New York, U.S.A.: Pergamon Press, 231-251. Galli, S.J., Zsebo, K.M., Geissler, E.N., 1994. The kit-ligand, stem-cell factor. Advances in Immunology 55, 1-96. Grier, R.L., DiGuardo, G., Myers, R., 1995. Mast cell tumour destruction in dogs by hypotonic solution. Journal of the Small Animal Practice 36, 385-388. Gerritsen, R.J., Teske, E., Kraus, J.S., Rutteman, G.R., 1998. Multi-agent chemotherapy for mast cell tumours in the dog. Vet Q 20, 28-31. Ginn, P.E., Fox, L.E., Brower, J.C., Gaskin, A., Kurzman, I.D., Kubilis, P.S., 2000. Immunohistochemical detection of p53 tumor-suppressor protein is a poor indicator of prognosis for canine cutaneous mast cell tumors. Veterinary Pathology 37, 33-39. Govier, S.M., 2003. Principles of treatment for mast cell tumors. Clinical Techniques in Small Animal Practice 18, 103-106. Gieger, T.L., Theon, A.P., Werner, J.A., McEntee, M.C., Rassnick, K.M., DeCock, H.E., 2003. Biologic behavior and prognostic factors for mast cell tumors of the canine muzzle: 24 dogs (1990-2001). Journal of Veterinary Internal Medicine 17, 687-692. Gieger, T., Northrup, N., Wall, M., 2005. Clinical management of mast cell tumors in dogs. Compendium Veterinary article #4, 56-75. Gu, L., Zhou, C., Liu, H., Gao, J., Li, Q., Mu, D., et al., 2010. Rapamycin sensitizes T-ALL cells to dexamethasone-induced apoptosis. Journal of Experimental and Clinical Cancer Research 29, 150. Hottendorf, G.H., Nielsen, S.W., 1967. Pathologic survey of 300 extirpated canine mastocytomas. Zentralbl Veterinarmed A 14, 272-281. Holtet, L., Bang, G., Larsen, B., 1982. Mastocytoma of the oral mucosa in a dog. Norsk Veterinaertidsskrift 94, 483-485. Harvey, H.J., Sykes, G., 1982. Tracheal mast cell tumor in a dog. Journal of the American Veterinary Medical Association 180, 1097-1100. Hortobagyi, G.N., Ames, F.C., Buzdar, A.U., Kau, S.W., McNeese, M.D., Paulus, D., et al., 1988. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 62, 2507-2516. Huang, E., Nocka, K., Beier, D.R., Chu, T.Y., Buck, J., Lahm, H.W., et al., 1990. The hematopoietic growth factor KL is encoded by the Sl locus and is the ligand of the c-kit receptor, the gene product of the W locus. Cell 63, 225-233. van der Hage, J.A., van de Velde, C.J., Julien, J.P., Tubiana-Hulin, M., Vandervelden, C., Duchateau, L., 2001. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. Journal of Clinical Oncology 19(22), 4224-4237. Hahn, K.A., King, G.K., Carreras, J.K., 2004. Efficacy of radiation therapy for incompletely resected grade III mast cell tumors in dogs: 31 cases. Journal of the American Veterinary Medical Association 224(1), 79-82. Irain, A.A., Nilsson, G., Ashman, L.K., Schwartz, L.B., 1995. Dexamethasone inhibits the development of mast cells from dispersed human fetal liver cells cultured in the presence of recombinant human stem cell factor. Immunology 84, 72-78. Ishiguro, T., Kadosawa, T., Takagi, S., Kim, G., Ohsaki, T., Bosnakovski, D., et al., 2003. Relationship of disease progression and plasma histamine concentrations in 11 dogs with mast cell tumors. Journal of Veterinary Internal Medicine 17, 194-198. Isotani, M., Ishida, N., Tominaga, M., Tamura, K., Yagihara, H., Ochi, S., et al., 2008. Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs. Journal of Veterinary Internal Medicine 22, 985-988. Johnson, B.W., Brightman, A.H., Whiteley, H.E., 1988. Conjunctival mast cell tumor in two dogs. Journal of the American Animal Hospital Association 24, 439-442. Jaffe, M.H., Hosgood, G., Taylor, H.W., Kerwin, S.C., Hedlung, C.S., Lopez, M.K., et al., 2000. Immunohistochemical and clinical evaluation of p53 in canine cutaneous mast cell tumors. Veterinary Pathology 37, 40-46. Kiupel, M., Webster, J.D., Kaneene, J.B., Miller, R., Yuzbasiyan-Gurkan, V., 2004. The use of KIT and tryptase expression patterns as prognostic tools for canine cutaneous mast cell tumors. Veterinary Pathology 41, 371-377. Kiupel, M., Webster, J.D., Miller, R.A., Kaneene, J.B., 2005. Impact of tumor depth, tumor location and multiple synchronous masses on the prognosis of canine cutaneous mast cell tumors. Journal of Veterinary Medicine 52, 280-286. Kumar, V., Abbas, A.K., Fausto, N., 2005. Robbins e Cotran – Patologia – Bases patologicas das doencas (7 ed.) Rio de Janeiro: Elsevier Co. Kiupel, M., Webster, J.D., Bailey, K.L., Best, S., DeLay, J., Detrisac, C.J., et al., 2011. Proposal of a 2-tier histologic grading system for canine cutaneous mast cell tumors to more accurately predict biological behavior. Veterinary Pathology 48(1), 147-155. London, C.A., Kisseberth, W.C., Galli, S.J., Geissler, E.N., Helfand, S.C., 1996. Expression of stem cell factor receptor (c-kit) by the malignant mast cells from spontaneous canine mast cell tumours. Journal of Comparative Pathology 115, 399-414. Linnekin, D., DeBerry, C.S., Mou, S., 1997. Lyn associates with the Juxtamembrane region of c-Kit and is activated by stem cell factor in hematopoietic cell lines and normal progenitor cells. The Journal of Biological Chemistry 272, 27450-27455. Ladue, T., Price, G.S., Dodge, R., Page, R.L., Thrall, D.E., 1998. Radiation therapy for incompletely resected canine mast cell tumors. Veterinary Radiology & Ultrasound 39(1), 57-62. London, C.A, Galli, S.J., Yuuki, T., Hu, Z.Q., Helfand, S.C., Geissler, E.N., 1999. Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. Experimental Hematology 27, 689-697. London, C.A., Seguin, B., 2003. Mast cell tumors in the dog. Veterinary Clinics of North America: Small Animal Practice 33, 473-489. Macy, D.W., 1986. Canine and feline mast cell tumors: biologic behavior, diagnosis, and therapy. Seminars in veterinary medicine and surgery small animal 1, 72-83. Misdorp, W., 1987. Incomplete surgery, local immunostimulation, and recurrence of some tumor types in dogs and cats. Vet Q 9(3), 279-286. Miller, M.A., Nelson, S.L., Turk, J.R., Pace, L.W., Brown, T.P., Show, D.P., et al., 1991. Cutaneous neoplasia in 340 cats. Veterinary Pathology 28, 389-395. McCaw, D.W., Miller, M.A., Ogilive, G.K., Withrow, S.J., Brewer, W.G., Klein, M.K., 1994. Response of canine mast cell tumors to treatment with oral prednisolone. Journal of Veterinary Internal Medicine 8(6), 406-408. Marino, D.J., Matthiesin, D.T., Stefanacci, J.D.,Moroff, S.D., 1995. Evaluation of dogs with digit masses: 117 cases. Journal of the American Veterinary Medical Association 207(6), 726-728. McCaw, D.L., Miller, M.A., Bergman, P.J., Withrow, S.J., Moore, A.S., Knapp, D.W., 1997. Vincristine therapy for mast cell tumors in dogs. Journal of Veterinary Internal Medicine 11, 375-378. Makris, A., Powles, T.J., Ashley, S.E., Chang, J., Hickish, T., Tidy, V.S., et al., 1998. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Annals of Oncology 9, 1179-1184. Ma, Y., Longley, B.J., Wang, X., Blount J.L., Langley, K., Caughey, G.H., 1999. Clustering of Activating Mutations in c-KIT/'s Juxtame mbrane Coding Region in Canine Mast Cell Neoplasms. Journal of Investigative Dermatology 112, 165-170. Moore, L.E., Garrett, L.D., De Bey, B., Biller, D.S., 2002. Spinal mast cell tumor in a dog. Journal of the American Animal Hospital Association 38, 67-70. Michels, G.M., Knapp, D.W., DeNicola, D.B., Glickman, N., Bonney, P., 2002. Prognosis following surgical excision of canine cutaneous mast cell tumors with histopathologically tumor-free versus nontumor-free margins: a retrospective study of 31 cases. Journal of the American Animal Hospital Association 38, 458-466. Misdorp, W., 2004. Mast cells and canine mast cell tumors. A review. Vet Q 26, 156-169. Morini, M., Bettini, G., Preziosi, R., Mandrioli, L., 2004. C-kit gene product (CD117) immunoreactivity in canine and feline paraffin sections. Journal of Histochemistry & Cytochemistry 52, 705-708. Murphy, S., Sparkes, A.H., Brearley, M.J., Smith, K.C., Blunden, A.S., 2004. Relationships between the histological grade of cutaneous mast cell tumours in dogs, their survival and the efficacy of surgical resection. Veterinary Record 154, 743-746. Maiolino, P., Cataldi, M., Paciello, O., Restucci, B., De Vico, G., 2005. Nucleomorphometric analysis of canine cutaneous mast cell tumors. Journal of Comparative Pathology 133, 209-211. Mullins, M.N., Dernel, W.S., Withrow, S.J., Ehrhart, E.J., Thamm, D.H., Lana, S.E., 2006. Evaluation of prognostic factors associated with outcome in dogs with multiple cutaneous mast cell tumors treated with surgery with and without adjuvant treatment: 54 cases (1998-2004). Journal of the American Veterinary Medical Association 228, 91-95. Matsuda, A., Tanaka, A., Muto, S., Ohmori, K., Furusaka, T., Jung, K., et al, 2010. A novel NF-kappaB inhibitor improves glucocorticoid sensitivity of canine neoplastic lymphoid cells by up-regulating expression of glucocorticoid receptors. Research of Veterinary Science 89, 378-382. Matsuda, A., Tanaka, A., Amagai, Y., Ohmori, K., Nishikawa, S., Xia, Y., et al., 2011. Glucocorticoid sensitivity depends on expression levels of glucocorticoid receptors in canine neoplastic mast cells. Veterinary Immunology and Immunopathology 144, 321-328. Nocka, K., Buck, J., Levi, E., Besmer, P., 1990. Candidate ligand for the c-kit transmembrane kinase receptor: KL, a fibroblast derived growth factor stimulates mast cells and erythroid progenitors. The EMBO Journal 9, 3287-3294. Nasir, L., Rutterman, G.R., Reid, S.W.J., Schulze, C., Argyle, D.J., 2001. Analysis of p53 mutational events and mdm2 amplification in canine soft-tissue sarcomas. Cancer Letters 174, 83-89. Northrup NC, Haron BG, Gieger TL, Brown, C.A., Carmichael, K.P., Garcia, A., et al, 2005. Variation among pathologists in the histologic grading of canine cutaneous mast cell tumors. Journal of Veterinary Diagnostic Investigation 17, 245-248. Northrup, N.C., Howerth, E.W., Harmon, B.G., Brown, C.A., Carmicheal, K.P., Garcia, A.P., et al., 2005. Variation among pathologists in the histologic grading of canine cutaneous mast cell tumors with uniform use of a single grading reference. Journal of Veterinary Diagnostic Investigation 17, 561-564. O'Keefe, D.A., 1990. Canine mast cell tumours. Veterinary Clinics of North America: Small Animal Practice 20, 1105-1115. Osuchowski, M.F., Welch, K., Siddiqui, J., Remick, D.G., 2006. Circulating cytokine/inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality. The Journal of Immunology 177, 1967-1974. Ozaki, K., Yamagami, T., Nomura, K., Narama, I., 2007. Prognostic significance of surgical margin, Ki-67 and Cyclin D1 protein expression in grade II canine cutaneous mass cell tumor. The Journal of Veterinary Medical Science 69, 1117-1121. Patnaik, A.K., MacEwen, E.G., Black, A.P., Luckow, S., 1982. Extracutaneous mast cell tumor in the dog. Veterinary Pathology 19, 608-615. Patnaik, A.K., Ehler, W.J., MacEwen, E.G., 1984. Canine cutaneous mast cell tumor. Morphologic grading and survival time in 83 dogs. Veterinary Pathology 21, 469-474. Page, C., Foreman, J.C., 1993. Introduction to mast cells and basophils. In: Page, C., Foreman, J.C., eds. Immunopharmacology of mast cells and basophils. Richmond, TX, U.S.A.: ExtremelyReliable Co, 1-4. Preziosi, R., Sarli, G., Paltrinieri, M., 2007. Multivariate survival analysis of histological parameters and clinical presentation in canine cutaneous mast cell tumours. Veterinary Research Communications 31, 287-296. Pinczowski, P., Torres Neto, R., Fabris, V.E., Laufer-Amorim, R., 2008. Mastocitoma cutaneo canino: variacao da graduacao histopatologica entre patologistas. Revista Clinica Veterinaria 77, 76-78. Poggiani, Sabrina dos Santos Costa, Terra, E.M., Neto, R.T., Costa,R.T., Amorim, R.L., 2012. Canine cutaneous mast cell tumor; biologic behavior and its correlation with prognostic indicators. Open Journal of Veterinary Medicine 2, 225-261. Ragaz, J., Baird, R., Rebbeck, P., Goldie, J., Coldman, A., Spinelli, J., 1985. Neoadjuvant (preoperative) chemotherapy for breast cancer. Cancer 56, 719-724. Rogers, K.S., 1996. Mast cell tumors. Dilemmas of diagnosis and treatment. Veterinary Clinics of North America: Small Animal Practice 26, 87. Rothwell, T.L.W., Howlett, C.R., Middleton, D.J., Griffiths, D.A., Duff, B.C., 1987. Skin neoplasms of dogs in Sydney. Australian Veterinary Journal 64, 161-164. Reguera, M.J., Rabanal, R.M., Puigdemont, A., Ferrer, L., 2000. Canine mast cell tumors express stem cell factor receptor. The American Journal of Dermatopathology 22, 49-54. Rungsipipat, A., Srichat, W., Charoenvisal, N.T., Manachai, N., Jearanai, W., Wangnaitham, S., 2009. Clinical evaluation of canine mast cell tumor treatment between combined vinblastine and prednisolone and single prednisolone. Comparative Clinical Pathology 18, 77-84. Simoes, J.P.C., Shoning, P., Butine, M., 1994. Prognosis of canine mast cell rumors: a comparison of three methods. Veterinary Pathology 31, 637-647. Serve, H., Yee, N.S., Stella, G., Sepp-Lorenzino, L., Tan, J.C., Besmer, P., 1995. Differential roles of PI3-Kinase and KIT Tyrosine-821 in KIT Receptor-mediated proliferation, survival and cell adhesion in mast cells. The EMBO Journal 14, 473-483. Seguin, B., Leibman, N.F., Bregazzi, V.S., Ogilvie, G.K., Powers, B.E., Dernell, W.S., et al., 2001. Clinical outcome of dogs with grade-II mast cell tumors treated with surgery alone: 55 cases (1996-1999). Journal of the American Veterinary Medical Association 218(7), 1120-1123. Setogushi, A., Okuda, M., Nishida, E., Yazawa, M., Ishizaka, T., Hongsh Hisasue, M., et al., 2001. Results of hyperamplification of centrosomes in naturally developing tumors of dogs. American Journal Veterinary Research 62, 1134-1141. Smith, S.J., Piliponsky, A.M., Rosenhead, F., Elchalal, U., Nagler, A., Levi-Schaffer, F., 2002. Dexamethasone inhibits maturation, cytokine production and Fc epsilon RI expression of human cord blood-derived mast cells. Clinical & Experimental Allergy 32, 906-913. Strefezzi, R.F.S., Xavier, J.G., Catǎo-Dias, J.L., 2003. Morphometry of canine cutaneous mast cell tumors. Veterinary Pathology 40, 268-275. Schmidt, S., Rainer, J., Ploner, C., Presul, E., Riml, S., Kofler, R., 2004. Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance. Cell Death & Differentiation 11(suppl. 1), S45-S55. Simpson, A.M., Ludwig, L.L.,, Newman, S.J., Bergman, P.J., Hottinger, H.A., Patnaik, A.K., 2004. Evaluation of surgical margins required for complete excision of cutaneous mast cell tumors in dogs. Journal of the American Veterinary Medical Association 224, 236-240. Sfiligoi, G., Rassnick, K.M., Scarlett, J.M., Northrup, N.C., Gieger, T.L., 2005. Outcome of dogs with mast cell tumors in the inguinal or perineal region versus other cutaneous locations: 124 cases (1990-2001). Journal of the American Veterinary Medical Association 226, 1368-1374. Sasai, K., Katoh, M., Fujita, D., Yamashita, M., Constantinoiu, C.C., Matsubayashi, M., et al., 2007. Monoclonal antibodies for the diagnosis of canine mastocytoma. Hybridoma (Larchmt) 26, 162-167. Stanclift, R.M., Gilson, S.D., 2008. Evaluation of neoadjuvant prednisone administration and surgical excision in treatment of cutaneous mast cell tumors in dogs. Journal of the American Veterinary Medical Association 232, 53-62. Strefezzi, R.F., Kleeb, S.R., Xavier, J.G., Catao-Dias, J.L., 2009. Prognostic indicators for mast cell tumors. Brazilian Journal of Veterinary Pathology 2(2), 110-121. Sahoo, S., Lester, S.C., 2009. Pathology of breast carcinomas after neoadjuvant chemotherapy. Archives of Pathology & Laboratory Medicine 133, 633-642. Strefezzi, R.F., Xavier, J.G., Kleeb, S.R., Catao-Dias J.L., 2009. Nuclear morphometry in cytopathology: a prognostic indicator for canine cutaneous mast cell tumors. Journal of Veterinary Diagnostic Investigation 21, 821-825. Tams, T.R., Macy, D.W., 1981. Canine mast cell tumors. Compendium continuing education for the practicing veterinarian 19, 869-878. Turrel, J.M., Kitchell, B.E., Miller, L.M., Theon, A., 1988. Prognostic factors for radiation treatment of mast cell tumors in 85 dogs. Journal of the American Veterinary Medical Association 193, 936-940. Takahashi, T., Kadosawa, T., Nagase, M.,Mochizuki, M., Matsunaga, ., Nishimura, R., 1997. Inhibitory effects of glucocorticoids on proliferation of canine mast cell tumor. The Journal of Veterinary Medical Science 59, 995-1001. Thamm, D.H., Mauldin, E.A., Vail, D.M., 1999. Prednisone and vinblastine chemotherapy for canine mast cell tumor—41 cases (1992-1997). Journal of Veterinary Internal Medicine 13, 491-497. Thamm, D.H., Vail, D.M., 2001. Mast cell tumors. In: Withrow, S.J., MacEwen, E.G., eds. Small Animal Clinical Oncology. Philadelphia, U.S.A.: WB Saunder, 261-279. Thamm, D.H., Turek, M.M., Vail, D.M., 2006. Outcome and prognostic factors following adjuvant prednisone/vinblastine chemotherapy for high-risk canine mast cell tumor: 61 cases. The Journal of Veterinary Medical Science 68, 581-587. Thamm, D.H., Vail, D.M., 2007. Mast cell tumors. In: Withrow, S.J., Vail, D.M., eds. Withrow & MacEwen's Small Animal Clinical Oncology (4th ed.) St Louis, MO: Saunders Elsevier, 402-424. Thompson, J.J., Pearl, D.L., Yager, J.A., Best, S.J., Coomber, B.L., Foster, R.A., 2011. Canine subcutaneous mast cell tumor: characterization and prognostic indices. Veterinary Pathology 48, 156-168. Teng, S.P., Hsu, W.L., Chiu, C.Y., Wong, M.L., Chang, S.C., 2012. Overexpression of p-glycoprotein, STAT3, phosphor-STAT3 and KIT in spontaneous canine cutaneous mast cell tumours before and after prednisolone treatment. The Veterinary Journal 193, 551-556. World Health Organization, 1978. Report of a consultation on the biological behavior and therapy of tumours of domestic animals. Geneva, World Health Organization. Weisse, C., Shofer, F.S., Sorenmo, K., 2002. Recurrence rate and sites for Grade II canine cutaneous tumors following complete surgical excision. Journal of the American Animal Hospital Association 38, 71-73. Wu, H., Hayashi, T., Inoue, M., 2006. Immunohistochemical expression of Mdm2 and p53 in canine cutaneous mast cell tumors. Journal of Veterinary Medicine. A, Physiology, Pathology, Clinical Medicine 53, 65-68. Webster, J.D., Yuzbasiyan-Gurkan, V., Kaneene, J.B., Miller, R., Resau, J.H., Kiupel, M., 2006. The role of c-KIT in tumorigenesis: evaluation in canine cutaneous mast cell tumors. Neoplasia 8, 104-111. Webster, J.D., Yuzbasiyan-Gurkan, V., Miller, R.A., Kaneene, J.B., Kiupel, M., 2007. Cellular proliferation in canine cutaneous mast cell tumors: associations with c-KIT and its role in prognostication. Veterinary Pathology 44, 298-308. Waljee, J.F., Newman, L.A., 2007. Neoadjuvant systemic therapy and the surgical management of breast cancer. Surgical Clinics of North America 87, 399-415. Welle, M.M., Bley, C.R., Howard, J., Rufenacht, S., 2008. Canine mast cell tumours: a review of the pathogenesis, clinical features, pathology and treatment. ESVD and ACVD 19, 321-329. Yager, J.A., Scott, D.W., 1993. The skin and appendages. In: Jubb, K.V.F., Kennedy, P.C., Palmer, N.C., eds. Pathology of Domestic Animals. California, U.S.A.: Academic Press, 531-738. Yoshikawa, H., Nakajima, Y., Tasaka, K., 1999. Glucocorticoid suppresses autocrine survival of mast cells by inhibiting IL-4 production and ICAM-1 expression. The Journal of Immunology 162, 6162-6170. Zontine, W.J., Meierhenry, E.F., Hicks, R.F., 1977. Perforated duodenal ulcer associated with mastocytoma in a dog: a case report. Journal of American Veterinary Radiology Society 18, 162-165. Zsebo, K.M., Williams, D.A., Geissler, E.N., Broudy, V.C., Martin, F.H., Atkins, H.L., et al., 1990. Stem cell factor is encoded at the Sl locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell 63, 213-224. Zsebo, K.M., Wypych, J., McNiece, I.K., Lu, H.S., Smith, K.A., Karkare, S.B., et al., 1990. Identification, purification, and biological characterization of hematopoietic stem cell factor from buffalo rat liver—conditioned medium. Cell 63, 195-201.
肥大細胞瘤為犬最常見的皮膚型腫瘤,具有多變的生物行為。Prednisolone在臨床上常被用作前導型藥物來治療肥大細胞瘤,且報告中指出其並不會造成投予後相關的併發症發生。本實驗的目的在於以口服prednisolone,40 mg/m2,一天一次,作為前導型藥物治療犬之肥大細胞瘤,隨後分為外科組與無外科組,並評估病患之局部腫瘤復發之情形、無復發間期及總存活時間。而犬肥大細胞瘤的組織分級則採用修飾型二分類組織分級系統來進行。本實驗將57隻已被診斷為肥大細胞瘤的患犬分為二組,分別是:(1)NA組,共29隻患犬,為無外科組;(2)NAS組,共28隻患犬,為外科組。在NAS組中之29隻患犬,若以三個月作為評估復發之期限,則有25隻(87.2%)於三個月內沒有出現腫瘤復發的情形;其無復發間期的中位數為39天,範圍從30天到71天。罹患低分級肥大細胞瘤之患犬,具有較長的無復發間期,但其無復發間期在罹患不同分級之肥大細胞瘤的患犬間(P = 0.294)並不具有顯著差異。另外,在NAS組中,於組織學上低分級的患犬其總存活時間中位數為225天(範圍從20天至1152天);而組織學上高分級的患犬,其總存活時間之中位數為180.5天(範圍從19天至850天);然而,兩者並不具有顯著差異(P = 0.114)。在NAS組之患犬,有九隻犬的肥大細胞瘤最大直徑超過5 cm或為高分級者,總存活時間中位數為355天,範圍從76到850天,平均總存活時間為293天。在NA組之患犬,總存活時間中位數為48天,範圍從6到622天。在NA組之患犬,有五隻犬的肥大細胞瘤最大直徑超過5 cm或為高分級者,總存活時間中位數為84天,範圍從33到183天,平均總存活時間為106天。對於給予prednisolone 進行治療者,結果顯示,61%之肥大細胞瘤對於給予prednisolone治療是有反應的,其中完全消退有一個,佔2.4%,而部分消退有24個,佔58.5%,平均消退百分比為75.4%。對於在組織學上屬於低分級或高分級的肥大細胞瘤,其對prednisolone治療的反應並不具顯著差異(P=0.805),其中達完全消退有一個,為高分級肥大細胞瘤;而達部分消退者,有16個為低分級、8個為高分級,而在低分級肥大細胞瘤之平均消退百分比為80.8%,高分級者則為54.2%。而腫瘤大小達到最大消退之中位時間為21天。總結以上結果,prednisolone可造成多數的(超過一半以上的)肥大細胞瘤顯著消退,即便是在高分級的肥大細胞瘤同樣可達到顯著消退。另外,罹患肥大細胞瘤之患犬,尤其是其肥大細胞瘤最大直徑大於5 cm或為高分級者,也許可以選擇先給予三週口服prednisolone前導型治療後,再進行手術切除團塊的方式來治療。

Mast cell tumors (MCTs) are most common cutaneous tumors in dogs, which have various biological behaviors. Prednisolone, as a neoadjuvant, is widely used in the treatment of MCTs, and without reported postoperative complications. The aims of this study were to evaluate the relapse free interval (RFI), overall survival time (OST), and locoregional recurrence of dogs with MCTs after receiving oral prednisolone at a dose of 40 mg/m2 body surface area (BSA) once daily and assigning to follow with or without surgery. The MCTs were graded by modified 2-tier histologic grading system. Fifty-seven dogs diagnosed with MCTs were assigned to two groups: (1) NA group, 29 dogs, not followed by surgery; (2) NAS group, 28 dogs, followed by surgical removal. When evaluated not exceed three months, 25 of 29 (87.2%) dogs in NAS group had no recurrence of their tumors within 3 months; the median RFI was 39 days, ranging from 30 to 71 days. Of NAS group, dogs with low grade MCTs had longer RFI; however, there were no significant difference (P = 0.294). The median OSTs of dogs in NAS group with low grade and high grade MCTs were 225 days (ranging from 20 to 1152 days) and 181 days (ranging from 19 to 850 days), respectively, and without significant difference (P = 0.114). Night dogs of NAS group and with the maximum diameter of the mass over 5 cm or with high grade MCTs, the median OST was 355 days, ranging from 76 to 850 days, and the mean OST was 293 days. Dogs in NA group, the median OST was 48 days, ranging from 6 to 622 days. Five dogs of NA group and with the maximum diameter of the mass over 5 cm or with high grade MCTs, the median OST was 84 days, ranging from 33 to 183 days, and the mean OST was 106 days. The overall response rate of prednisolone was 61% and mean response was 75.4%. One mass had complete response [CR] (2.4%) and 24 masses had partial response [PR](58.5%). There was no significant difference comparing low grade with high grade MCTs (P=0.805). There was only one high grade MCT had CR. In addition, there were 16 low grade MCTs and 8 high grade MCTs had PR. In low grade MCTs, the mean regression percentage was 80.8%; in the other hand, it was 54.2% in high grade MCTs. The median time-span for reaching maximal tumor regression was 21 days. In conclusion, prednisolone can induce dramatic MCTs reduction even with high grade tumors. Based on the observations from this study, treatment of neoadjuvant prednisolone for 3 weeks followed by surgical removal might be recommended for patients with MCTs, especially with the maximum diameter of the mass over 5 cm or high grade MCTs.
其他識別: U0005-0708201513122700
Rights: 同意授權瀏覽/列印電子全文服務,2015-08-12起公開。
Appears in Collections:獸醫學系所

Files in This Item:
File SizeFormat Existing users please Login
nchu-104-7101038012-1.pdf6.34 MBAdobe PDFThis file is only available in the university internal network   
Show full item record

Google ScholarTM


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.